The injection of tacrolimus

A technology of tacrolimus and products, applied in allergic diseases, antibacterial drugs, drug combinations, etc., can solve problems such as difficulties, and achieve the effect of eliminating the reduction of drug content

Inactive Publication Date: 2007-10-17
CHONG KUN DONG CORP
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] However, since each surfactant has different physical values, such as hydrophilic-lipophilic balance (HLB) and critical micelle concentration (CMC), and has different characteristics in the application field, it is considered that selecting an appropriate surface active agent Active agent to prepare stable tacrolimus injection is very difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Tacrolimus injection using polyethylene glycol 15-hydroxystearate

[0049] Dissolve 5 mg of tacrolimus and 100 mg of polyethylene glycol 15-hydroxystearate (Solutol® HS 15, BASF company) in 1 ml of absolute ethanol, then filter with a 0.2 μm filter to prepare in injectable form.

Embodiment 2

[0051] Tacrolimus injection using polyethylene glycol 15-hydroxystearate

[0052]Dissolve 5 mg of tacrolimus and 200 mg of polyethylene glycol 15-hydroxystearate (Solutol(R) HS 15, BASF company) in 1 ml of absolute ethanol, then filter with a 0.2 μm filter to make a usable in injectable form.

Embodiment 3

[0054] Tacrolimus injection using polyethylene glycol 15-hydroxystearate

[0055] Dissolve 5 mg of tacrolimus in 1 ml of absolute ethanol, 300 mg of polyethylene glycol 15-hydroxystearate (Solutol(R) HS 15, BASF company), and then filter with a 0.2 μm filter to make available in injectable form.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to tacrolimus injection comprising tacrolimus as an active ingredient, macrogol 15 hydroxystearate as a surfactant and a non-aqueous solvent.

Description

technical field [0001] The invention relates to a tacrolimus injection, which contains tacrolimus as an active component, polyethylene glycol 15-hydroxystearate as a surfactant and a non-aqueous solvent. Background technique [0002] Tacrolimus of the present invention is the compound 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxyl-3-methoxycyclohexyl)-1-methylethylene base]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo[22.3.1.0. 4.9 ] International Nonproprietary Name of Octacosyl-18-ene-2,3,10,16-tetraone (hereinafter referred to as tacrolimus). [0003] Tacrolimus, which has immunosuppressive and antimicrobial activity, is indicated for the treatment and / or prophylaxis of the following diseases and conditions: [0004] Rejection of an organ or tissue transplant; [0005] Graft-versus-host reaction resulting from bone marrow transplantation; [0006] autoimmune diseases; [0007] and infections caused by pathogenic microorganisms. [0008] Tacrolimus is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08
CPCA61K9/0019A61K47/14A61K47/10A61K9/08A61P31/04A61P37/02A61P37/06A61K31/44
Inventor 李相俊申凞钟李奭圭尹志训
Owner CHONG KUN DONG CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products